{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:02:32Z","timestamp":1794304952386,"version":"4.9.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":112,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI168251"],"award-info":[{"award-number":["AI168251"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI168251"],"award-info":[{"award-number":["AI168251"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI168251"],"award-info":[{"award-number":["AI168251"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institutes of Health,United States","award":["AI168917"],"award-info":[{"award-number":["AI168917"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-026-01449-1","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T01:05:02Z","timestamp":1776733502000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Structural and genetic signatures of two classes of HCV E2 neutralizing face antibodies from non-human primates immunized with a recombinant E1E2"],"prefix":"10.1038","volume":"11","author":[{"given":"Yen T. K.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick","family":"Giang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn A.","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey T.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Netanel","family":"Tzarum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian A.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansun","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn L.","family":"Stanfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"1449_CR1","doi-asserted-by":"publisher","first-page":"637","DOI":"10.7326\/M16-2575","volume":"166","author":"O Falade-Nwulia","year":"2017","unstructured":"Falade-Nwulia, O. et al. Oral direct-acting agent therapy for Hepatitis C virus infection: a systematic review. Ann. Intern. Med. 166, 637\u2013648 (2017).","journal-title":"Ann. Intern. Med."},{"key":"1449_CR2","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","volume":"153","author":"F Kanwal","year":"2017","unstructured":"Kanwal, F. et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 153, 996\u20131005.e1 (2017).","journal-title":"Gastroenterology"},{"key":"1449_CR3","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.jhep.2016.07.012","volume":"65","author":"H Midgard","year":"2016","unstructured":"Midgard, H. et al. HCV epidemiology in high-risk groups and the risk of reinfection. J. Hepatol. 65, S33\u2013S45 (2016).","journal-title":"J. Hepatol."},{"key":"1449_CR4","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.4254\/wjh.v13.i10.1234","volume":"13","author":"N Echeverr\u00eda","year":"2021","unstructured":"Echeverr\u00eda, N. et al. In the era of rapid mRNA-based vaccines: Why is there no effective Hepatitis C virus vaccine yet? World J. Hepatol. 13, 1234\u20131268 (2021).","journal-title":"World J. Hepatol."},{"key":"1449_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1126\/science.abn9884","volume":"378","author":"A Torrents de la Pe\u00f1a","year":"2022","unstructured":"Torrents de la Pe\u00f1a, A. et al. Structure of the Hepatitis C virus E1E2 glycoprotein complex. Science 378, 263\u2013269 (2022).","journal-title":"Science"},{"key":"1449_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39659-z","volume":"14","author":"MC Metcalf","year":"2023","unstructured":"Metcalf, M. C. et al. Structure of engineered Hepatitis C virus E1E2 ectodomain in complex with neutralizing antibodies. Nat. Commun. 14, 3980 (2023).","journal-title":"Nat. Commun."},{"key":"1449_CR7","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41586-024-07783-5","volume":"633","author":"EH Augestad","year":"2024","unstructured":"Augestad, E. H. et al. The Hepatitis C virus envelope protein complex is a dimer of heterodimers. Nature 633, 704\u2013709 (2024).","journal-title":"Nature"},{"key":"1449_CR8","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1126\/science.282.5390.938","volume":"282","author":"P Pileri","year":"1998","unstructured":"Pileri, P. et al. Binding of Hepatitis C virus to CD81. Science 282, 938\u201341 (1998).","journal-title":"Science"},{"key":"1449_CR9","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/nature05654","volume":"446","author":"MJ Evans","year":"2007","unstructured":"Evans, M. J. et al. Claudin-1 is a Hepatitis C virus co-receptor required for a late step in entry. Nature. 446, 801\u20135 (2007).","journal-title":"Nature"},{"key":"1449_CR10","doi-asserted-by":"publisher","first-page":"5017","DOI":"10.1093\/emboj\/cdf529","volume":"21","author":"E Scarselli","year":"2002","unstructured":"Scarselli, E. et al. The human scavenger receptor class B type I is a novel candidate receptor for the Hepatitis C virus. EMBO J. 21, 5017\u201325 (2002).","journal-title":"EMBO J."},{"key":"1449_CR11","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/nature07684","volume":"457","author":"A Ploss","year":"2009","unstructured":"Ploss, A. et al. Human occludin is a Hepatitis C virus entry factor required for infection of mouse cells. Nature 457, 882\u20136 (2009).","journal-title":"Nature"},{"key":"1449_CR12","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nrmicro3098","volume":"11","author":"BD Lindenbach","year":"2013","unstructured":"Lindenbach, B. D. & Rice, C. M. The ins and outs of Hepatitis C virus entry and assembly. Nat. Rev. Microbiol. 11, 688\u2013700 (2013).","journal-title":"Nat. Rev. Microbiol."},{"key":"1449_CR13","doi-asserted-by":"publisher","first-page":"11095","DOI":"10.1128\/JVI.79.17.11095-11104.2005","volume":"79","author":"A Owsianka","year":"2005","unstructured":"Owsianka, A. et al. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the Hepatitis C virus E2 envelope glycoprotein. J. Virol. 79, 11095\u201311104 (2005).","journal-title":"J. Virol."},{"key":"1449_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nm1698","volume":"14","author":"M Law","year":"2008","unstructured":"Law, M. et al. Broadly neutralizing antibodies protect against Hepatitis C virus quasispecies challenge. Nat. Med. 14, 25\u20137 (2008).","journal-title":"Nat. Med."},{"key":"1449_CR15","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1128\/JVI.01661-14","volume":"89","author":"C Harman","year":"2015","unstructured":"Harman, C. et al. A view of the E2-CD81 interface at the binding site of a neutralizing antibody against Hepatitis C virus. J. Virol. 89, 492\u2013501 (2015).","journal-title":"J. Virol."},{"key":"1449_CR16","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1126\/science.1243876","volume":"342","author":"L Kong","year":"2013","unstructured":"Kong, L. et al. Hepatitis C virus E2 envelope glycoprotein core structure. Science 342, 1090\u20134 (2013).","journal-title":"Science"},{"key":"1449_CR17","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.3389\/fimmu.2018.01315","volume":"9","author":"N Tzarum","year":"2018","unstructured":"Tzarum, N., Wilson, I. A. & Law, M. The neutralizing face of Hepatitis C virus E2 envelope glycoprotein. Front. Immunol. 9, 1315 (2018).","journal-title":"Front. Immunol."},{"key":"1449_CR18","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.coviro.2015.04.001","volume":"11","author":"L Kong","year":"2015","unstructured":"Kong, L., Jackson, K. N., Wilson, I. A. & Law, M. Capitalizing on knowledge of Hepatitis C virus neutralizing epitopes for rational vaccine design. Curr. Opin. Virol. 11, 148\u201357 (2015).","journal-title":"Curr. Opin. Virol."},{"key":"1449_CR19","doi-asserted-by":"publisher","first-page":"6205","DOI":"10.1073\/pnas.1114927109","volume":"109","author":"E Giang","year":"2012","unstructured":"Giang, E. et al. Human broadly neutralizing antibodies to the envelope glycoprotein complex of Hepatitis C virus. Proc. Natl. Acad. Sci. USA 109, 6205\u20136210 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1449_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.immuni.2021.12.003","volume":"55","author":"T Weber","year":"2022","unstructured":"Weber, T. et al. Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization. Immunity 55, 341\u2013354.e7 (2022).","journal-title":"Immunity"},{"key":"1449_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abb5642","volume":"6","author":"N Tzarum","year":"2020","unstructured":"Tzarum, N. et al. An alternate conformation of HCV E2 neutralizing face as an additional vaccine target. Sci. Adv. 6, eabb5642 (2020).","journal-title":"Sci. Adv."},{"key":"1449_CR22","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41586-021-03913-5","volume":"598","author":"A Kumar","year":"2021","unstructured":"Kumar, A. et al. Structural insights into Hepatitis C virus receptor binding and entry. Nature 598, 521\u2013525 (2021).","journal-title":"Nature"},{"key":"1449_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36183-y","volume":"14","author":"A Kumar","year":"2023","unstructured":"Kumar, A. et al. Regions of Hepatitis C virus E2 required for membrane association. Nat. Commun. 14, 433 (2023).","journal-title":"Nat. Commun."},{"key":"1449_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aav1882","volume":"5","author":"N Tzarum","year":"2019","unstructured":"Tzarum, N. et al. Genetic and structural insights into broad neutralization of Hepatitis C virus by human VH1-69 antibodies. Sci. Adv. 5, eaav1882 (2019).","journal-title":"Sci. Adv."},{"key":"1449_CR25","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.coviro.2019.02.004","volume":"34","author":"F Chen","year":"2019","unstructured":"Chen, F., Tzarum, N., Wilson, I. A. & Law, M. VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design. Curr. Opin. Virol. 34, 149\u2013159 (2019).","journal-title":"Curr. Opin. Virol."},{"key":"1449_CR26","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.chom.2018.10.009","volume":"24","author":"AI Flyak","year":"2018","unstructured":"Flyak, A. I. et al. HCV broadly neutralizing antibodies use a CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design. Cell Host Microbe 24, 703\u2013716.e3 (2018).","journal-title":"Cell Host Microbe"},{"key":"1449_CR27","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.immuni.2024.03.001","volume":"57","author":"CO Ogega","year":"2024","unstructured":"Ogega, C. O. et al. Convergent evolution and targeting of diverse E2 epitopes by human broadly neutralizing antibodies are associated with HCV clearance. Immunity 57, 890\u2013903.e6 (2024).","journal-title":"Immunity"},{"key":"1449_CR28","doi-asserted-by":"publisher","first-page":"a038778","DOI":"10.1101\/cshperspect.a038778","volume":"10","author":"NC Wu","year":"2020","unstructured":"Wu, N. C. & Wilson, I. A. Influenza hemagglutinin structures and antibody recognition. Cold Spring Harb. Perspect. Med. 10, a038778 (2020).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"1449_CR29","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1146\/annurev-immunol-032712-095916","volume":"31","author":"D Corti","year":"2013","unstructured":"Corti, D. & Lanzavecchia, A. Broadly neutralizing antiviral antibodies. Annu. Rev. Immunol. 31, 705\u201342 (2013).","journal-title":"Annu. Rev. Immunol."},{"key":"1449_CR30","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1002\/hep.32632","volume":"77","author":"E Barnes","year":"2023","unstructured":"Barnes, E., Cooke, G. S., Lauer, G. M. & Chung, R. T. Implementation of a controlled human infection model for evaluation of HCV vaccine candidates. Hepatology. 77, 1757\u20131772 (2023).","journal-title":"Hepatology"},{"key":"1449_CR31","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMsb2109093","volume":"385","author":"TJ Liang","year":"2021","unstructured":"Liang, T. J., Feld, J. J., Cox, A. L. & Rice, C. M. Controlled human infection model - fast track to HCV vaccine? N. Engl. J. Med. 385, 1235\u20131240 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1449_CR32","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1126\/science.1139247","volume":"316","author":"RA Gibbs","year":"2007","unstructured":"Gibbs, R. A. et al. Evolutionary and biomedical insights from the rhesus macaque genome. Science 316, 222\u201334 (2007).","journal-title":"Science"},{"key":"1449_CR33","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.molimm.2021.04.010","volume":"135","author":"J Lemaitre","year":"2021","unstructured":"Lemaitre, J. et al. Non-human primate models of human respiratory infections. Mol. Immunol. 135, 147\u2013164 (2021).","journal-title":"Mol. Immunol."},{"key":"1449_CR34","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00251-016-0921-2","volume":"68","author":"GY Yu","year":"2016","unstructured":"Yu, G. Y. et al. Cynomolgus macaque (Macaca fascicularis) immunoglobulin heavy chain locus description. Immunogenetics 68, 417\u2013428 (2016).","journal-title":"Immunogenetics"},{"key":"1449_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taab036","volume":"28","author":"S Antinori","year":"2021","unstructured":"Antinori, S. et al. Non-human primate and human malaria: past, present and future. J. Travel Med. 28, taab036 (2021).","journal-title":"J. Travel Med."},{"key":"1449_CR36","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd2638","volume":"371","author":"RS Roark","year":"2021","unstructured":"Roark, R. S. et al. Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. Science 371, eabd2638 (2021).","journal-title":"Science"},{"key":"1449_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl9605","volume":"14","author":"WT He","year":"2022","unstructured":"He, W. T. et al. Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques. Sci. Transl. Med. 14, eabl9605 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1449_CR38","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.immuni.2020.12.018","volume":"54","author":"N V\u00e1zquez Bernat","year":"2021","unstructured":"V\u00e1zquez Bernat, N. et al. Rhesus and cynomolgus macaque immunoglobulin heavy-chain genotyping yields comprehensive databases of germline VDJ alleles. Immunity 54, 355\u2013366.e4 (2021).","journal-title":"Immunity"},{"key":"1449_CR39","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/nar\/gkg085","volume":"31","author":"MP Lefranc","year":"2003","unstructured":"Lefranc, M. P. IMGT, the international immunogenetics database. Nucleic Acids Res. 31, 307\u201310 (2003).","journal-title":"Nucleic Acids Res."},{"key":"1449_CR40","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.3389\/fimmu.2017.01407","volume":"8","author":"A Ramesh","year":"2017","unstructured":"Ramesh, A. et al. Structure and diversity of the rhesus macaque immunoglobulin loci through multiple de novo genome assemblies. Front. Immunol. 8, 1407 (2017).","journal-title":"Front. Immunol."},{"key":"1449_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.818440","volume":"13","author":"M Kaduk","year":"2022","unstructured":"Kaduk, M., Corcoran, M. & Karlsson Hedestam, G. B. Addressing IGHV gene structural diversity enhances immunoglobulin repertoire analysis: Lessons from rhesus macaque. Front. Immunol. 13, 818440 (2022).","journal-title":"Front. Immunol."},{"key":"1449_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13642","volume":"7","author":"MM Corcoran","year":"2016","unstructured":"Corcoran, M. M. et al. Production of individualized V gene databases reveals high levels of immunoglobulin genetic diversity. Nat. Commun. 7, 13642 (2016).","journal-title":"Nat. Commun."},{"key":"1449_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1506348","volume":"15","author":"Y Guo","year":"2024","unstructured":"Guo, Y., Waltari, E., Lu, H., Sheng, Z. & Wu, X. Novel rhesus macaque immunoglobulin germline genes identified by three sequencing approaches. Front. Immunol. 15, 1506348 (2024).","journal-title":"Front. Immunol."},{"key":"1449_CR44","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1053\/j.gastro.2019.11.282","volume":"158","author":"F Chen","year":"2020","unstructured":"Chen, F. et al. Antibody responses to immunization with HCV envelope glycoproteins as a baseline for B-cell-based vaccine development. Gastroenterology. 158, 1058\u20131071.e6 (2020).","journal-title":"Gastroenterology"},{"key":"1449_CR45","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.immuni.2021.02.013","volume":"54","author":"F Chen","year":"2021","unstructured":"Chen, F. et al. Functional convergence of a germline-encoded neutralizing antibody response in rhesus macaques immunized with HCV envelope glycoproteins. Immunity 54, 781\u2013796.e4 (2021).","journal-title":"Immunity"},{"key":"1449_CR46","doi-asserted-by":"publisher","first-page":"6367","DOI":"10.1016\/j.vaccine.2010.06.084","volume":"28","author":"SE Frey","year":"2010","unstructured":"Frey, S. E. et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 28, 6367\u201373 (2010).","journal-title":"Vaccine"},{"key":"1449_CR47","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1086\/655902","volume":"202","author":"R Ray","year":"2010","unstructured":"Ray, R. et al. Characterization of antibodies induced by vaccination with Hepatitis C virus envelope glycoproteins. J. Infect. Dis. 202, 862\u20136 (2010).","journal-title":"J. Infect. Dis."},{"key":"1449_CR48","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.immuni.2025.12.002","volume":"59","author":"A Peres","year":"2026","unstructured":"Peres, A. et al. Population-level genomic analysis of immunoglobulin loci variation in rhesus macaques reveals extensive germline diversity. Immunity 59, 213\u2013228.e6 (2026).","journal-title":"Immunity"},{"key":"1449_CR49","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btae144","volume":"40","author":"WD Lees","year":"2024","unstructured":"Lees, W. D., Saha, S., Yaari, G. & Watson, C. T. Digger: directed annotation of immunoglobulin and T cell receptor V, D, and J gene sequences and assemblies. Bioinformatics. 40, btae144 (2024).","journal-title":"Bioinformatics"},{"key":"1449_CR50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.coviro.2021.07.003","volume":"50","author":"N Frumento","year":"2021","unstructured":"Frumento, N., Flyak, A. I. & Bailey, J. R. Mechanisms of HCV resistance to broadly neutralizing antibodies. Curr. Opin. Virol. 50, 23\u201329 (2021).","journal-title":"Curr. Opin. Virol."},{"key":"1449_CR51","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0263-7855(93)87010-3","volume":"11","author":"ML Connolly","year":"1993","unstructured":"Connolly, M. L. The molecular surface package. J. Mol. Graph. 11, 139\u201341 (1993).","journal-title":"J. Mol. Graph."},{"key":"1449_CR52","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1084\/jem.132.2.211","volume":"132","author":"TT Wu","year":"1970","unstructured":"Wu, T. T. & Kabat, E. A. An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J. Exp. Med. 132, 211\u201350 (1970).","journal-title":"J. Exp. Med."},{"key":"1449_CR53","doi-asserted-by":"publisher","first-page":"D678","DOI":"10.1093\/nar\/gkac1003","volume":"51","author":"RD Olson","year":"2023","unstructured":"Olson, R. D. et al. Introducing the Bacterial and Viral Bioinformatics Resource Center (BV-BRC): a resource combining PATRIC, IRD and ViPR. Nucleic Acids Res. 51, D678\u2013D689 (2023).","journal-title":"Nucleic Acids Res."},{"key":"1449_CR54","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0300-9084(03)00004-X","volume":"85","author":"A Goffard","year":"2003","unstructured":"Goffard, A. & Dubuisson, J. Glycosylation of hepatitis C virus envelope proteins. Biochimie 85, 295\u2013301 (2003).","journal-title":"Biochimie"},{"key":"1449_CR55","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz6225","volume":"6","author":"L He","year":"2020","unstructured":"He, L. et al. Proof of concept for rational design of Hepatitis C virus E2 core nanoparticle vaccines. Sci. Adv. 6, eaaz6225 (2020).","journal-title":"Sci. Adv."},{"key":"1449_CR56","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.3390\/v15051151","volume":"15","author":"E Gomez-Escobar","year":"2023","unstructured":"Gomez-Escobar, E., Roingeard, P. & Beaumont, E. Current Hepatitis C vaccine candidates based on the induction of neutralizing antibodies. Viruses 15, 1151 (2023).","journal-title":"Viruses"},{"key":"1449_CR57","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3389\/fimmu.2018.01032","volume":"9","author":"R Burm","year":"2018","unstructured":"Burm, R., Collignon, L., Mesalam, A. A. & Meuleman, P. Animal models to study Hepatitis C virus infection. Front. Immunol. 9, 1032 (2018).","journal-title":"Front. Immunol."},{"key":"1449_CR58","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1053\/j.gastro.2018.08.060","volume":"156","author":"JR Bailey","year":"2019","unstructured":"Bailey, J. R., Barnes, E. & Cox, A. L. Approaches, progress, and challenges to Hepatitis C vaccine development. Gastroenterology 156, 418\u2013430 (2019).","journal-title":"Gastroenterology"},{"key":"1449_CR59","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.3389\/fimmu.2018.01396","volume":"9","author":"LJ Str\u00f6h","year":"2018","unstructured":"Str\u00f6h, L. J., Nagarathinam, K. & Krey, T. Conformational flexibility in the CD81-binding site of the Hepatitis C virus glycoprotein E2. Front. Immunol. 9, 1396 (2018).","journal-title":"Front. Immunol."},{"key":"1449_CR60","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1056\/NEJMra1204186","volume":"368","author":"GJ Nabel","year":"2013","unstructured":"Nabel, G. J. Designing tomorrow\u2019s vaccines. N. Engl. J. Med. 368, 551\u201360 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1449_CR61","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1146\/annurev-immunol-041015-055515","volume":"34","author":"DR Burton","year":"2016","unstructured":"Burton, D. R. & Hangartner, L. Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu. Rev. Immunol. 34, 635\u201359 (2016).","journal-title":"Annu. Rev. Immunol."},{"key":"1449_CR62","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/nri891","volume":"2","author":"DR Burton","year":"2002","unstructured":"Burton, D. R. Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2, 706\u201313 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"1449_CR63","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.tibtech.2008.08.002","volume":"26","author":"PR Dormitzer","year":"2008","unstructured":"Dormitzer, P. R., Ulmer, J. B. & Rappuoli, R. Structure-based antigen design: a strategy for next generation vaccines. Trends Biotechnol. 26, 659\u201367 (2008).","journal-title":"Trends Biotechnol."},{"key":"1449_CR64","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000503","volume":"8","author":"C Schulthei\u00df","year":"2024","unstructured":"Schulthei\u00df, C. et al. B cells expressing mutated IGHV1-69-encoded antigen receptors related to virus neutralization show lymphoma-like transcriptomes in patients with chronic HCV infection. Hepatol. Commun. 8, e0503 (2024).","journal-title":"Hepatol. Commun."},{"key":"1449_CR65","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6617","volume":"370","author":"WC Warren","year":"2020","unstructured":"Warren, W. C. et al. Sequence diversity analyses of an improved rhesus macaque genome enhance its biomedical utility. Science 370, eabc6617 (2020).","journal-title":"Science"},{"key":"1449_CR66","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.cell.2019.04.012","volume":"177","author":"KM Cirelli","year":"2019","unstructured":"Cirelli, K. M. et al. Slow delivery immunization enhances HIV neutralizing antibody and germinal center responses via modulation of immunodominance. Cell 177, 1153\u20131171.e28 (2019).","journal-title":"Cell"},{"key":"1449_CR67","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41592-020-01056-5","volume":"18","author":"H Cheng","year":"2021","unstructured":"Cheng, H., Concepcion, G. T., Feng, X., Zhang, H. & Li, H. Haplotype-resolved de novo assembly using phased assembly graphs with hifiasm. Nat. Methods 18, 170\u2013175 (2021).","journal-title":"Nat. Methods"},{"key":"1449_CR68","first-page":"656","volume":"12","author":"WJ Kent","year":"2002","unstructured":"Kent, W. J. BLAT\u2014the BLAST-like alignment tool. Genome Res. 12, 656\u201364 (2002).","journal-title":"Genome Res."},{"key":"1449_CR69","doi-asserted-by":"publisher","first-page":"W276","DOI":"10.1093\/nar\/gkac240","volume":"50","author":"F Madeira","year":"2022","unstructured":"Madeira, F. et al. Search and sequence analysis tools services from EMBL-EBI in 2022. Nucleic Acids Res. 50, W276\u2013W279 (2022).","journal-title":"Nucleic Acids Res."},{"key":"1449_CR70","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1093\/bioinformatics\/15.4.305","volume":"15","author":"P Gouet","year":"1999","unstructured":"Gouet, P., Courcelle, E. & Stuart, D. I. & M\u00e9toz, F. ESPript: analysis of multiple sequence alignments in PostScript. Bioinformatics 15, 305\u20138 (1999).","journal-title":"Bioinformatics"},{"key":"1449_CR71","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.1016\/j.molimm.2008.05.022","volume":"45","author":"KR Abhinandan","year":"2008","unstructured":"Abhinandan, K. R. & Martin, A. C. Analysis and improvements to Kabat and structurally correct numbering of antibody variable domains. Mol. Immunol. 45, 3832\u20139 (2008).","journal-title":"Mol. Immunol."},{"key":"1449_CR72","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jim.2007.09.017","volume":"329","author":"T Tiller","year":"2008","unstructured":"Tiller, T. et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods 329, 112\u201324 (2008).","journal-title":"J. Immunol. Methods"},{"key":"1449_CR73","doi-asserted-by":"publisher","first-page":"e0232311","DOI":"10.1371\/journal.pone.0232311","volume":"15","author":"R Lieu","year":"2020","unstructured":"Lieu, R. et al. Rapid and robust antibody Fab fragment crystallization utilizing edge-to-edge beta-sheet packing. PLoS ONE. 15, e0232311 (2020).","journal-title":"PLoS ONE"},{"key":"1449_CR74","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/978-1-4939-8976-8_30","volume":"1911","author":"JR Bailey","year":"2019","unstructured":"Bailey, J. R., Urbanowicz, R. A., Ball, J. K., Law, M. & Foung, S. K. H. Standardized method for the study of antibody neutralization of HCV pseudoparticles (HCVpp). Methods Mol. Biol. 1911, 441\u2013450 (2019).","journal-title":"Methods Mol. Biol."},{"key":"1449_CR75","doi-asserted-by":"publisher","unstructured":"Chen, F. et al. The conserved bridging domain on HCV E1E2 glycoprotein complex is targeted by neutralizing antibodies from diverse lineages. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.11.05.686883 (2025).","DOI":"10.1101\/2025.11.05.686883"},{"key":"1449_CR76","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1084\/jem.20021756","volume":"197","author":"B Bartosch","year":"2003","unstructured":"Bartosch, B., Dubuisson, J. & Cosset, F. L. Infectious Hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197, 633\u201342 (2003).","journal-title":"J. Exp. Med."},{"key":"1449_CR77","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/hep.20542","volume":"41","author":"D Lavillette","year":"2005","unstructured":"Lavillette, D. et al. Characterization of host-range and cell entry properties of the major genotypes and subtypes of Hepatitis C virus. Hepatology 41, 265\u201374 (2005).","journal-title":"Hepatology"},{"key":"1449_CR78","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1073\/pnas.0501275102","volume":"102","author":"JC Meunier","year":"2005","unstructured":"Meunier, J. C. et al. Evidence for cross-genotype neutralization of Hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc. Natl. Acad. Sci. USA 102, 4560\u20135 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1449_CR79","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1128\/JVI.02877-14","volume":"89","author":"YP Li","year":"2015","unstructured":"Li, Y. P., Ramirez, S., Mikkelsen, L. & Bukh, J. Efficient infectious cell culture systems of the Hepatitis C virus (HCV) prototype strains HCV-1 and H77. J. Virol. 89, 811\u201323 (2015).","journal-title":"J. Virol."},{"key":"1449_CR80","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","volume":"276","author":"Z Otwinowski","year":"1997","unstructured":"Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307\u201326 (1997).","journal-title":"Methods Enzymol."},{"key":"1449_CR81","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658\u2013674 (2007).","journal-title":"J. Appl. Crystallogr."},{"key":"1449_CR82","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1039\/C9ME00020H","volume":"4","author":"D Schritt","year":"2019","unstructured":"Schritt, D. et al. Repertoire builder: high-throughput structural modeling of B and T cell receptors. Mol. Syst. Des. Eng. 4, 761\u2013768 (2019).","journal-title":"Mol. Syst. Des. Eng."},{"key":"1449_CR83","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1107\/S0907444902016657","volume":"58","author":"PD Adams","year":"2002","unstructured":"Adams, P. D. et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. D Biol. Crystallogr. 58, 1948\u201354 (2002).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"1449_CR84","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126\u201332 (2004).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"1449_CR85","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1107\/S0907444909042073","volume":"66","author":"VB Chen","year":"2010","unstructured":"Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12\u201321 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"1449_CR86","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jmb.2007.05.022","volume":"372","author":"E Krissinel","year":"2007","unstructured":"Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774\u201397 (2007).","journal-title":"J. Mol. Biol."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01449-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01449-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01449-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:02:48Z","timestamp":1786460568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01449-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1449"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01449-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.10.07.680784","asserted-by":"object"}]},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.T.W. is co-founder\/CSO of Clareo Biosciences, Inc. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"160"}}